StockUS listing USCUBTNYSE MKTHealthcareCapital Destroyer

Curative Biotechnology Inc(CUBT) Stock Analysis | Healthcare

USD --+0.00%
Reward31Low
Risk79High
75%Data
USD —+0.00 (+0.00%) Previous close · NYSE MKT
Market cap 5.34M
Reward Ratingⓘ31 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ79 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CUBT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Curative Biotechnology Inc?

, a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications.

AI Brief Pro

The brief on Curative Biotechnology Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Curative Biotechnology Inc?

, a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 5.34M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (31)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.489
Insider Activity
12M windowNo data
No insider activity data available for this ticker.